君实生物上半年尚未盈利 PD-1产品仍处爬坡期|直击业绩会

科创板记者 史士云
Sep 08, 2025

《科创板日报》9月8日讯(记者 史士云)在与信达生物(01801.HK)、百济神州(688235.SH)、恒瑞医药(600267.SH)共同组成的国产PD-1“四小龙” 阵营中,在其他三家均实现盈利的当下,君实生物(688180.SH)迄今仍未突破盈利关口。 对此,在今日(9月8日)召开的中期业绩会上,君实生物执行董事、总经理、首席执行官邹建军表示:“公司将继续保持对前沿治疗领域和更多候选药物的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10